These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 39342168)

  • 1. RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
    Shi JX; Zhang ZC; Yin HZ; Piao XJ; Liu CH; Liu QJ; Zhang JC; Zhou WX; Liu FC; Yang F; Wang YF; Liu H
    Mol Cancer; 2024 Sep; 23(1):213. PubMed ID: 39342168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferroptosis: a critical mechanism of N
    Wei Q; Xue C; Li M; Wei J; Zheng L; Chen S; Duan Y; Deng H; Tang F; Xiong W; Zhou M
    Sci China Life Sci; 2024 Jun; 67(6):1119-1132. PubMed ID: 38811442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of RNA methylation in tumor immunity and its potential in immunotherapy.
    Li Y; Jin H; Li Q; Shi L; Mao Y; Zhao L
    Mol Cancer; 2024 Jun; 23(1):130. PubMed ID: 38902779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m6A modification of RNA in cervical cancer: role and clinical perspectives.
    Gao Y; Guo Q; Yu L
    RNA Biol; 2024 Jan; 21(1):49-61. PubMed ID: 39344658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regulatory mechanisms of N6-methyladenosine modification in ferroptosis and its implications in disease pathogenesis.
    Tao X; Kang N; Zheng Z; Zhu Z; Ma J; He W
    Life Sci; 2024 Oct; 355():123011. PubMed ID: 39181316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.
    Sun X; Wang H; Pu X; Wu Y; Yuan X; Wang X; Lu H
    Cancer Gene Ther; 2024 Sep; 31(9):1315-1322. PubMed ID: 38834772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Identification and Immunotherapy Response Analysis of the Prognostic Signature Associated With m6A, Cuproptosis-Related, Ferroptosis-Related lncRNA in Endometrial Cancer.
    Qian Y; Chen H; Miao P; Ma R; Lu B; Hu C; Fan R; Xu B; Chen B
    Cancer Rep (Hoboken); 2024 Sep; 7(9):e70009. PubMed ID: 39324703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of m6A RNA methylation in cancer metabolism.
    An Y; Duan H
    Mol Cancer; 2022 Jan; 21(1):14. PubMed ID: 35022030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new perspective on hematological malignancies: m6A modification in immune microenvironment.
    Yang S; Xu L; Zhuang H; Li F; Lu Y
    Front Immunol; 2024; 15():1374390. PubMed ID: 38868768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL14-Mediated m6A Modification of
    Gu X; Song Y; Liu X; Cheng Z; Min J; Zhang Y
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):298. PubMed ID: 39206905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifaceted bioinformatic analysis of m6A-related ferroptosis and its link with gene signatures and tumour-infiltrating immune cells in gliomas.
    Yang Y; Hao L; Guiyang L; Haozhe P
    J Cell Mol Med; 2024 Sep; 28(17):e70060. PubMed ID: 39248438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
    Lin H; Wang Y; Wang P; Long F; Wang T
    Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4.
    Meng X; Wang Z; Yang Q; Liu Y; Gao Y; Chen H; Li A; Li R; Wang J; Sun G
    Cell Death Dis; 2024 Oct; 15(10):729. PubMed ID: 39368999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of N6‑methyladenosine modification in tumor development and potential therapeutic strategies (Review).
    Pu X; Wu Y; Ji Q; Fu S; Zuo H; Chu L; Tang H; Wan M; Wang X; Xu M
    Int J Oncol; 2023 Jun; 62(6):. PubMed ID: 37203412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functions of RNA N6-methyladenosine modification in cancer progression.
    Chen B; Li Y; Song R; Xue C; Xu F
    Mol Biol Rep; 2019 Apr; 46(2):2567-2575. PubMed ID: 30911972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder.
    Mu S; Zhao K; Zhong S; Wang Y
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
    Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
    Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into N6-methyladenosine and programmed cell death in cancer.
    Liu L; Li H; Hu D; Wang Y; Shao W; Zhong J; Yang S; Liu J; Zhang J
    Mol Cancer; 2022 Jan; 21(1):32. PubMed ID: 35090469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N
    Quan C; Belaydi O; Hu J; Li H; Yu A; Liu P; Yi Z; Qiu D; Ren W; Ma H; Gong G; Ou Z; Chen M; Sun Y; Chen J; Zu X
    Front Immunol; 2021; 12():697026. PubMed ID: 34526985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response.
    Wu Y; He H; Zheng K; Qin Z; Cai N; Zuo S; Zhu X
    Pigment Cell Melanoma Res; 2024 Jul; 37(4):496-509. PubMed ID: 38624045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.